243 related articles for article (PubMed ID: 31475103)
1. Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives.
Cavallari I; Urso L; Sharova E; Pasello G; Ciminale V
Front Oncol; 2019; 9():740. PubMed ID: 31475103
[TBL] [Abstract][Full Text] [Related]
2. Circulating biomarkers in malignant pleural mesothelioma.
Viscardi G; Di Natale D; Fasano M; Brambilla M; Lobefaro R; De Toma A; Galli G
Explor Target Antitumor Ther; 2020; 1(6):434-451. PubMed ID: 36046389
[TBL] [Abstract][Full Text] [Related]
3. A liquid biopsy for detecting circulating mesothelial precursor cells: A new biomarker for diagnosis and prognosis in mesothelioma.
Duong BTV; Wu L; Green BJ; Bavaghar-Zaeimi F; Wang Z; Labib M; Zhou Y; Cantu FJP; Jeganathan T; Popescu S; Pantea J; de Perrot M; Kelley SO
EBioMedicine; 2020 Nov; 61():103031. PubMed ID: 33045471
[TBL] [Abstract][Full Text] [Related]
4. Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
Ferrari L; Carugno M; Mensi C; Pesatori AC
Front Oncol; 2020; 10():445. PubMed ID: 32318342
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
[TBL] [Abstract][Full Text] [Related]
6. [Malignant pleural mesothelioma: diagnosis and treatment].
Delourme J; Dhalluin X; Cortot AB; Lafitte JJ; Scherpereel A
Rev Pneumol Clin; 2013 Feb; 69(1):26-35. PubMed ID: 23333048
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-98 is a prognostic factor for asbestos-induced mesothelioma.
Kim K; Ko Y; Oh H; Ha M; Kang J; Kwon EJ; Kang JW; Kim Y; Heo HJ; Kim G; Kim JW; Kim YH
J Toxicol Environ Health A; 2020 Feb; 83(3):126-134. PubMed ID: 32114955
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
9. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
10. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis and staging of malignant pleural mesothelioma].
Sohrab S; Konietzko N
Pneumologie; 2002 Jun; 56(6):382-7. PubMed ID: 12063622
[TBL] [Abstract][Full Text] [Related]
12. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
13. New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
Rossini M; Rizzo P; Bononi I; Clementz A; Ferrari R; Martini F; Tognon MG
Front Oncol; 2018; 8():91. PubMed ID: 29666782
[TBL] [Abstract][Full Text] [Related]
14. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
15. New DNA Methylation Signals for Malignant Pleural Mesothelioma Risk Assessment.
Cugliari G; Allione A; Russo A; Catalano C; Casalone E; Guarrera S; Grosso F; Ferrante D; Sculco M; La Vecchia M; Pirazzini C; Libener R; Mirabelli D; Magnani C; Dianzani I; Matullo G
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34071989
[TBL] [Abstract][Full Text] [Related]
16. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Zhang W; Wu X; Wu L; Zhang W; Zhao X
Ann Transl Med; 2015 Aug; 3(13):182. PubMed ID: 26366399
[TBL] [Abstract][Full Text] [Related]
17. Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan.
Lee LJ; Lin CK; Pan CH; Cheng Y; Chang YY; Liou SH; Wang JD
BMJ Open; 2018 Dec; 8(12):e021063. PubMed ID: 30530573
[TBL] [Abstract][Full Text] [Related]
18. Pleural Mesothelioma with No Asbestos Exposure: A Case Report.
Batahar SA; Ouradi O; Elidrissi S; Amro L
J Clin Diagn Res; 2016 Nov; 10(11):OD07-OD08. PubMed ID: 28050426
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis and prognosis-review of biomarkers for mesothelioma.
Sun HH; Vaynblat A; Pass HI
Ann Transl Med; 2017 Jun; 5(11):244. PubMed ID: 28706912
[TBL] [Abstract][Full Text] [Related]
20. Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure.
de Gennaro G; Dragonieri S; Longobardi F; Musti M; Stallone G; Trizio L; Tutino M
Anal Bioanal Chem; 2010 Dec; 398(7-8):3043-50. PubMed ID: 20924566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
